Perrigo Completes Strategic Move to Sell Infant Formula Business to MeridianMade

Perrigo Company plc, a prominent player in the consumer self-care sector, has confirmed a major strategic shift by agreeing to sell its infant formula business to MeridianMade. This milestone agreement, valued at up to $175 million, includes $40 million in cash upon closing and potential future payments based on performance metrics until 2030. In this article, we explore the details of this transaction and its implications for both companies and the industry as a whole.

Perrigo’s decision to divest its infant formula segment aligns with its Three-S strategy, aimed at Stabilizing, Streamlining, and Strengthening the company. By simplifying its portfolio, Perrigo intends to enhance its focus on delivering over-the-counter (OTC) health products that cater to the everyday needs of consumers. This divestiture is expected to improve Perrigo's profit margins and significantly reduce foreseeable capital expenditures, allowing the company to allocate resources more efficiently toward its core self-care offerings.

Albert Manzone, the Interim President and CEO of Perrigo, described the transaction as a crucial step towards achieving the goals outlined in their strategic plan. He highlighted the dedication and hard work of the Infant Formula team, which has positioned the business for a successful transition. “MeridianMade's singular focus on infant nutrition, along with its commitment to quality, safety, and reliability, makes them an ideal custodian for this important product line,” he stated.

MeridianMade is recognized for its specialization in infant nutrition, offering safe and high-quality formula to American families. The acquisition is set to bolster its infrastructure and operational capabilities, ensuring a consistent supply of affordable infant nutrition products. MeridianMade’s leadership, including CEO Ron Belldegrun and President Mia Funt, expressed optimism about the acquisition. They emphasized their commitment to maintaining responsible stewardship of store-brand infant formulas, providing families with access to nutritious options without breaking the bank.

Until the completion of the sale, both Perrigo’s Infant Formula division and MeridianMade will operate independently. Perrigo will continue to manage the infant formula business with the same focus on quality and customer service that parents expect. The deal is expected to close in the first half of 2027, pending standard regulatory approvals and customary closing conditions.

The financial implications of this divestiture are significant. Perrigo's earnings are anticipated to better reflect the financial profile of its core business, excluding the infant formula segment from quarterly earnings reports after the third quarter of 2026. A non-cash impairment charge between $275 million to $375 million is expected to appear in Perrigo's fourth-quarter financial statements, a reflection of the transaction’s further financial adjustments.

Despite these changes, Perrigo generated substantial revenue from its infant formula business, reporting $380 million in net sales over the past year with an adjusted operating income of $8 million. The decision to divest is not just a financial maneuver but a strategic repositioning that aims to enhance the overall performance of the company moving forward.

As the landscape of consumer self-care continues evolving, the divestiture of Perrigo's infant formula business marks a noteworthy shift in focus, allowing the company to pursue new avenues for growth while ensuring that infant nutrition remains a priority in the market. MeridianMade, with its dedicated resources and commitment to excellence in infant nutrition, is poised to lead this significant segment into its next chapter.

In conclusion, the divestiture by Perrigo to MeridianMade represents an essential step in its strategic journey, paving the way for a more streamlined and focused approach to its operations, ultimately benefiting consumers and stakeholders alike. With this move, both companies are set to thrive in their respective markets, reinforcing the importance of quality and safety in consumer health products.